{"name":"NovoCure GmbH","slug":"novocure-gmbh","ticker":"","exchange":"","domain":"novocuregmbh.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Immune checkpoint inhibitors or docetaxel","genericName":"Immune checkpoint inhibitors or docetaxel","slug":"immune-checkpoint-inhibitors-or-docetaxel","indication":"Non-small cell lung cancer (Phase 3 trials)","status":"phase_3"}]}],"pipeline":[{"name":"Immune checkpoint inhibitors or docetaxel","genericName":"Immune checkpoint inhibitors or docetaxel","slug":"immune-checkpoint-inhibitors-or-docetaxel","phase":"phase_3","mechanism":"This is a combination approach using immune checkpoint inhibitors to enhance anti-tumor immunity and/or docetaxel chemotherapy to directly kill cancer cells.","indications":["Non-small cell lung cancer (Phase 3 trials)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNT3o2bXlvS1JWWnJqT2N3TU9XQ0pNWHBzdmxqWl9pWkZKTWZheEtIQkdyVHRQb200LXFma0xJMF9pTk41bjNHSzByOTVCR2RWRXZWeHlpTUR1dEtCREtsUFJHWlI3ZGtlUHRKTVNNTEhKZU5FX3dxMWdBQURQeFVTZ3JkWF9hZkpoLUExcXhWTHR3Q1k2UW1aZ2NR?oc=5","date":"2025-12-02","type":"pipeline","source":"BioCentury","summary":"Novo Nordisk’s Miriam Frieden to lead BD at Lundbeck - BioCentury","headline":"Novo Nordisk’s Miriam Frieden to lead BD at Lundbeck","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPamxXSFhUckt3MnZNZ0dERUg1anJPUl9iMzJYanVSdFJweVNHRVVicklOeWNISFhfa1MzSGNvdHVyRkxrNmh4SkRtdFpnbklCQmJXWGZ3TEJrZE1NYWtsM2FZVGdNNER6aW5XYzViU0hKemo5dlNMRDE2VDAtMG5Tc3plMXUzQQ?oc=5","date":"2025-09-16","type":"regulatory","source":"Medical Device Network","summary":"Novocure obtains approval for Optune Lua device in Japan to treat NSCLC - Medical Device Network","headline":"Novocure obtains approval for Optune Lua device in Japan to treat NSCLC","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNdzQzR3ZEWnlVUGJXUkRoaFltNW9DU2s5LVF1aFhWVEQ5QXlHNmlNeURHTjNDejV4YkxZY1VuSFRrYmp0VTRlTzF1MnpLblQ1TlRSRWt3RjRHUzRfVnNQaFlDTWJaMDlaaGV2VmdFa0s1TTE4MzVZWUI5U0ZKMEJWNTFoemoxUnZHWWdMMkg4N25nUDR3VEtVa21RV1hZS250OEFPd0J0LTVvZ3hT?oc=5","date":"2025-08-21","type":"pipeline","source":"BioWorld News","summary":"Novocure files PMA for use of Optune in pancreatic cancer treatment - BioWorld News","headline":"Novocure files PMA for use of Optune in pancreatic cancer treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOSFVhaS1lVnNhMW9KZ19nNVE3Yl9sc3JQaGx3eW1kd2lWUWZtSEUwenlSWnJWeFhJMFlMck5ZdTJHTWt1bkJ0LUZrYXEwSEN6ZFNUUzBiTkhuNHlGdG12Vk1ZTFBscE9IeWRBTzhuc3B2X2FwWllJbnU5MVdyYnE2cDM1SnRHdkNCM19KTnRVd2lpSmVxaTBOdEduWGlBTXJ1blEwbzFMam9mNlpYalc1dFZfdTZOcjNYTUp6bTBCWWVPUQ?oc=5","date":"2024-10-17","type":"regulatory","source":"Medical Economics","summary":"FDA approves treatment for lung cancer that disrupts cancer cells with electric fields - Medical Economics","headline":"FDA approves treatment for lung cancer that disrupts cancer cells with electric fields","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE5EY1VkWE1EODd3cFVWVFQ0STA2aEtqNEJRbTVaZW1qdTJjVUlUZjY0ZV9tV1pZZDhjaWVJTktFaDNydS1nbjctLTlzWDNkYkZyQTJ2YmpGMXJ3bC1nTlIteUNab2JZVFo3QmV2bVhRdVI3aGM?oc=5","date":"2024-09-26","type":"pipeline","source":"Taylor & Francis Online","summary":"Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer - Taylor & Francis Online","headline":"Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPc1g5WTdZN0xWTE5IdHUzSDVoWS1JRW1EUzhJdG9RTmJ5OGN6cm5ERWFDVHBYRHJEd09CYUVrWjRsaW5ENlZxakZhNW5JcHROV1NpcE5oVmxkLVVCazlxUzAyOV9NblQ2VG9NLUV3bGk3QWQ3WEtMNGpsNmlfTUo2N2hYaHNEWVc2MGtlMmM5VXU2dk82ZUNqbm5uT0gtY21UTTJfOHpiLXpSM1Z1UTVYeEthTlFydw?oc=5","date":"2024-01-29","type":"regulatory","source":"BioWorld News","summary":"FDA accepts Novocure’s PMA application for lung cancer treatment technology - BioWorld News","headline":"FDA accepts Novocure’s PMA application for lung cancer treatment technology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE50eVdFSGtQWUpha1U2X0tZSHE2MExkaDMxLTBmTHpXVXJzM3BwSmUyUDNpN2tSQ2h5VmxSYUdSMWVuQzM4azNGU2N4TDllVVlwTnNUdURpT1gweFBCVTRrZWE4SlVmOHBxcTYyQTgtUm9kT1NJSkVXMnVxU0IxQQ?oc=5","date":"2022-11-30","type":"regulatory","source":"Medical Device Network","summary":"Health Canada approves Novocure’s Optune to treat glioblastoma - Medical Device Network","headline":"Health Canada approves Novocure’s Optune to treat glioblastoma","sentiment":"positive"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}